+1-888-308-5802     
News Contact Us

Prenatal and New-born Genetic Testing Market outlook with industry review and forecasts

Author : Rahul Sankrityayan | Published Date : 2019-03-27 

Sema4’s latest DNA screening test is a typical precedent underlining the advancements across prenatal & new-born genetic testing market. Recently launched, this pioneering DNA screening test, dubbed as Sema4 Natalis, is particularly designed to detect nearly 193 childhood onset genetic diseases, using highly advanced next generation DNA sequencing. Reportedly, the test would be also including a complete pharmacogenetic analysis of how a newborn is likely to respond to the 38 medications that are commonly prescribed. Indeed, this supplemental newborn screening test is touted to be one of the most futuristic ones of its kind to have been released in prenatal and new-born genetic testing market , especially against a backdrop where nearly 7.9 million infants globally are detected with birth defects.

The United States: One of the top-notch growth avenues for prenatal and new-born genetic testing market

Newborn and prenatal screening was actually initiated due to its potential to prevent severe genetic disabilities. In fact, according to latest report, currently more than 98% of the 4 million newborns in the United States undergo genetic screening annually for over 30 treatable genetic, endocrine, infectious, and metabolic diseases within first week of their birth. Not to mention, this has left a remunerative impact on U.S. prenatal and new-born genetic testing market, which pegged a valuation of approximately USD 2 billion in 2017.

Get a Sample Copy of this Report @ www.gminsights.com/request-sample/detail/1906

It is therefore irrefutable that the underlining principle that lurks behind the introduction of groundbreaking solutions in prenatal and new-born genetic testing industry is the dire necessity of reducing mortality and morbidity rate in infants having inherent genetic disorders. Experts claim that identifying the heritable conditions at early stage can improve a child’s long-term health and survival. However, as it has been observed, the number and type of genetic disorders that are included in newborn screening vary geographically. Say for instance, presently there are 34 core hereditary conditions and 26 secondary conditions that are recommended by the United States Department of Health and Human Services for newborn screening. Thus, it can be inferred that administrative backup is a major factor influencing prenatal and new-born genetic testing industry outlook.

How advancements in prenatal diagnosis is impacting the overall industry trend?

Corresponding to the continuous intervention of technological advancements, the present practice of prenatal screening, i.e. testing genetic abnormalities even in the fetus, has undergone a dramatic transformation of sorts. Non-invasive cell-free DNA screening for fetal aneuploidy, whole-exome sequencing, chromosomal microarray analysis, and screening for subchromosomal abnormalities, have indeed sent out waves of anticipation in prenatal and newborn screening market. Enlisted below are some of the latest initiatives encompassing this particular business vertical, expected to leave a palpable impact on the overall industry share over the coming years.

  • LifeCell, one of the leading names in India prenatal and new-born genetic testing market, has recently launched ‘Pentastic’ – a prenatal test designed to detect genetic abnormalities in fetus. Allegedly, this ultrasound biochemistry-based blood test is recommended for would be mothers in the first trimester of pregnancy i.e., between 11 to 13 weeks. As claimed by experts, Pentastic test is likely to gain an advantage over other conventional prenatal screening, as it incorporates five analytes (PAPP-A + free hCGß + AFP + Inhibin-A + PIGF), against its contemporaries which include only two analytes. Experts have been already raving about the technology claiming it to prominently disrupt the prenatal and new-born genetic testing industry product terrain.
  • Renowned American molecular diagnostics company Myriad Genetics has recently made to the headlines with its acquisition of Counsyl. The USD 375 million worth deal, reportedly is a strategic move by former to strengthen its portfolio in the rapidly evolving prenatal and newborn genetic testing market with Counsyl’s Prelude test portfolio. Through the alliance, Myriad Genetics would be merging Counsyl’s extensive reproductive health tests and existing preventive care business into a new unit, dubbed as Myriad Women’s Health. For the records, this new unit would be solely focusing on reproductive healthcare providers and OB-Gyns.

It is imperative to mention that the unprecedented advancements in genomic medicine are critically impacting prenatal diagnosis, subsequently boosting prenatal and new-born genetic testing industry size. Of course, the full potential of the business space can only be realized if these groundbreaking innovations are introduced in a substantiation-based ethically responsible manner and securitized after implementation. However, with genetic abnormalities and chromosomal disorders in infants becoming a global concern, prenatal and new-born genetic testing industry, in all likelihood, would reach remarkable stature in terms of innovations and revenue. Global Market Insights, Inc. forecasts the overall business space to exceed a valuation of USD 7 billion by 2024.

About Author

Rahul Sankrityayan

Rahul Sankrityayan

Fortified with a post-graduate degree in Computer Applications, Rahul Sankrityan writes for Fractovia, where he pens down news and articles spanning across segments of technology industry that excite him on a day-to-day basis. Rahul comes with a rich experience in technical field as well as writing. He can be contacted at- [email protected] | https://twitter.com/sankritsays

Related News

Synthetic Food Market Projections, Industry Outlook, Business Outlook by 2024

Published Date: 2019-08-22         Author: Rahul Sankrityayan

Global Market Insights, Inc. has released a new research study on Synthetic Food Market analysis 2018-2023 inclusive of one or more factors covering regional opportunities, application landscape, product demand trends, and end-use portfolio of the industry over the forecast timeframe. The repor... Read More

Non-Alcoholic Beer Market Insights, Industry Projections, Regional Analysis by 2024

Published Date: 2019-08-22         Author: Rahul Sankrityayan

Global Market Insights, Inc. has announced the launch of Non-Alcoholic Beer Market, a comprehensive study enumerating the latest price trends and pivotal drivers rendering a positive impact on the industry landscape. Further, the report is inclusive of the competitive terrain of this vertical in add... Read More

Food Enzymes Market 2019 Analysis, Industry Strategy, Business Prospects by 2024

Published Date: 2019-08-22         Author: Rahul Sankrityayan

Global Market Insights, Inc. has added a new report on Food Enzymes Market that provides a comprehensive review of this industry with respect to the driving forces influencing the market size. Comprising the current and future trends defining the dynamics of this industry vertical, this report also ... Read More

© 2019 Fractovia. All Rights Reserved